Welcome to our dedicated page for Oruka Therapeutics SEC filings (Ticker: ORKA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a clinical-stage biotech filing can feel like decoding an immunology textbook. Oruka Therapeutics’ 10-K details half-life extension technology, while each 8-K announces new trial data or financing rounds that can move the share price overnight. Finding R&D burn rates, dilution clauses, or executive grants across hundreds of pages is time-consuming and error-prone.
Our platform removes that friction. Stock Titan delivers AI-powered summaries for every Oruka Therapeutics SEC document—so understanding Oruka Therapeutics SEC documents with AI becomes immediate. Get real-time alerts the moment an Oruka Therapeutics 8-K material event is posted, review an Oruka Therapeutics quarterly earnings report 10-Q filing with plain-English highlights, or track Oruka Therapeutics Form 4 insider transactions real-time without scanning multiple PDFs. Whether you need the Oruka Therapeutics annual report 10-K simplified or a quick Oruka Therapeutics earnings report filing analysis, our expert layer translates biotech jargon into actionable facts.
Dig deeper into what matters for a pipeline company: cash runway, trial endpoints, and insider confidence. Use our dashboard to:
- Monitor Oruka Therapeutics insider trading Form 4 transactions and spot trends in executive stock activity.
- Compare quarter-over-quarter R&D spending across 10-Qs.
- Surface key compensation metrics inside the latest Oruka Therapeutics proxy statement executive compensation.
On July 1, 2025, Oruka Therapeutics, Inc. (ORKA) filed a Form 4 reporting that Chief Operating Officer Laura Lee Sandler received an employee stock option covering 25,000 shares of common stock at an exercise price of $11.80 per share. The option expires on June 30, 2035 and vests 25 % on July 1, 2026, with the remaining 75 % vesting in equal monthly installments thereafter (1⁄48 per month). After the grant, Sandler beneficially owns 25,000 derivative securities; no non-derivative share transactions were disclosed. The filing reflects an incentive-based award rather than an open-market purchase or sale, resulting in no immediate cash flow or share-count impact for investors.
On 07/01/2025, Oruka Therapeutics, Inc. (ORKA) filed a Form 3 reporting the initial beneficial ownership of its newly appointed Chief Operating Officer, Laura Lee Sandler.
- Direct ownership: 213,084 shares of common stock.
- Derivative securities: • Warrant covering 99,996 shares at an exercise price of $7.80, expiring 07/14/2034. Vesting schedule: 25% on 04/03/2025, remaining shares vest monthly over the subsequent three years. • Employee stock option for 137,500 shares at $12.50, expiring 01/21/2035; vests 1/48 monthly beginning 01/01/2025.
- Potential total ownership: 450,580 shares if all derivatives vest and are exercised.
The disclosure signals meaningful insider alignment through equity ownership and a performance-linked vesting structure. No other transactions or financial metrics were included in this filing.
Amendment No. 25 to Schedule 13D discloses that India-based Tractors & Farm Equipment Ltd (TAFE), TAFE Motors & Tractors Ltd and chair Mallika Srinivasan collectively hold roughly 16.3 % of AGCO’s 74.6 million outstanding shares (≈12.15 million shares). The filing follows a comprehensive settlement signed on 30 Jun 2025 that resets the long-standing strategic relationship between the two companies.
Key agreements
- Cooperation Agreement: imposes a perpetual stand-still: the Reporting Persons will vote in line with AGCO’s Board and will not raise their ownership above the “Ownership Cap” (≈16.3 %) except on defined change-of-control triggers. They must also participate proportionately in future AGCO buybacks.
- Buyback Agreement: AGCO Holding B.V. will sell its 20.7 % stake in TAFE (2.389 million shares) back to TAFE for US$260 million. Completion is pending Indian procedural approvals.
- Intellectual Property Agreement: Exclusive rights to the “Massey Ferguson” brand for tractors in India, Nepal and Bhutan will transfer to TAFE when the Buyback closes.
- Arbitration & Litigation Settlements: All cross-border disputes and brand-related suits will be withdrawn, eliminating legal overhang.
Strategic implications
- AGCO receives US$260 million cash and exits its minority position in TAFE.
- Stable 16 % shareholder alignment reduces near-term takeover risk and supports Board initiatives.
- Brand transfer limits AGCO’s direct exposure to the fast-growing Indian tractor market but clarifies marketing rights.
FAQ
What is the current stock price of Oruka Therapeutics (ORKA)?
What is the market cap of Oruka Therapeutics (ORKA)?
What is the core focus of Oruka Therapeutics?
Which therapeutic programs are central to Oruka's pipeline?
How does Oruka differentiate its therapies from current treatments?
What role does research and development play in Oruka's business model?
What are the potential advantages of the half-life extension technology employed by Oruka?
In which markets is Oruka Therapeutics positioned to compete?
How does Oruka ensure the scientific integrity of its clinical programs?
Who are the likely beneficiaries of Oruka's therapies?
How does Oruka demonstrate its commitment to established industry practices?
